UK Markets closed

Director/PDMR Shareholding

Acacia Pharma Group plc
·2-min read

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Cambridge, UK and Indianapolis, US – 13 October 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that on 12 October 2020, the Company's Employee Benefit Trust ("EBT") transferred 60,000 ordinary shares of 0.2 pence in the Company (the "Ordinary Shares") to Gary Gemignani following the vesting of share awards granted under the Company's Performance Share Plan.

Following the transfer of the Ordinary Shares referred to above. Gary Gemignani holds 60,000 Ordinary Shares, representing 0.07 per cent. of the total issued share capital of the Company.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Gary Gemignani

2

Reason for the notification

a)

Position/status

Chief Financial Officer/PDMR

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Acacia Pharma Group plc

b)

LEI

213800SLDKXWKT6E3381

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument



Identification code

Ordinary Shares of £0.02 each







GB00BYWF9Y76

b)

Nature of the transaction

Allotment of Ordinary Shares following vesting of share award under the Company's Performance Share Plan

c)

Price(s) and volume(s)

60,000 Ordinary Shares at a price of £0.02 pence per share

d)

Aggregated information
- Aggregated volume
- Price

N/A

e)

Date of the transaction

12 October 2020

f)

Place of the transaction

Euronext Brussels (XBRU)

Contacts

Acacia Pharma Group plc
Mike Bolinder, CEO
Gary Gemignani, CFO
+44 1223 919760 / +1 317 505 1280
IR@acaciapharma.com

International Media
Mark Swallow, Frazer Hall, David Dible
Citigate Dewe Rogerson
+44 20 7638 9571
acaciapharma@citigatedewerogerson.com

US Investors
LifeSci Advisors
Irina Koffler
+1 917-734-7387
ikoffler@lifesciadvisors.com

Media in Belgium and the Netherlands
Chris Van Raemdonck
+32 499 58 55 31
chrisvanraemdonck@telenet.be